Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113605 | 0.89 | PTGS2 (0.50) | PTGS2PTGS1GABRA2GABRB2SMN1; SMN2 | |
| SCHEMBL21113572 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1GABRA2GABRB2 | |
| SCHEMBL5593885 | 0.77 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL213892 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5594726 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5594653 | 0.77 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL27605216 | 0.76 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL6175669 | 0.75 | PTGS1 (0.54) | PTGS2PTGS1GABRA2GABRB2SMN1; SMN2 | |
| SCHEMBL28111728 | 0.75 | PTGS1 (0.54) | PTGS2PTGS1GABRA2GABRB2SMN1; SMN2 | |
| SCHEMBL6906119 | 0.75 | PTGS2 (0.67) | PTGS2PTGS1GABRA2GABRB2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | claimed |
| CN-1575182-A | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORP (US) | 2005-02-02 | — | — | CN | claimed |
| CN-1561246-A | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORP (US) | 2005-01-05 | — | — | CN | claimed |
| CN-1527709-A | Therapeutic combination for cardiovascular and inflammatory indications | — | 2004-09-08 | — | — | CN | claimed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
| CN-100372539-C | Pharmaceutical composition comprising a combination of a bisphosphonate, a COX-2 inhibitor and paclitaxel for the treatment of malignancies | NOVARTIS AG (CH) | 2008-03-05 | — | — | CN | disclosed |
| CN-1771034-A | Combinations of peroxisome proliferators-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PHARMACIA CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | disclosed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | disclosed |
| CN-1642544-A | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors | PHARMACIA CORP (US) | 2005-07-20 | — | — | CN | disclosed |
| CN-1638760-A | Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin | PHARMACIA CORP (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1638759-A | Pharmaceutical composition comprising a bisphosphonate and a COX-2 inhibitor for the treatment of bone diseases | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| CN-1575182-A | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORP (US) | 2005-02-02 | — | — | CN | disclosed |
| CN-1561246-A | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORP (US) | 2005-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885PTGS1 1824/4885GABRA2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.